Agilent acquires Proscia in deal worth up to $270m
Agilent (A) will acquire Proscia for up to $270m, including $240m upfront and $30m for performance milestones. The deal aims to enhance Agilent's pathology portfolio with Proscia's digital pathology software, Concentriq Dx, which has FDA clearance. Proscia serves over 4,000 labs and 16 top pharma companies, according to Agilent. The acquisition is expected to close in Agilent's fiscal year 2027.
How this was made
The 30-second read
Why it matters
The Proscia deal adds a software and AI component, potentially creating cross‑selling opportunities and higher margin revenue.
Market read
A material M&A announcement for a mid‑cap U.S. stock, likely to move the share price and affect the diagnostics sector.
What to watch
Potential regulatory review and the performance of Proscia's AI platform post‑integration.
Background
Agilent recently completed a $950M acquisition of Biocare Medical, indicating an ongoing strategy to expand its diagnostics offerings.
Ticker impact
Agilent Technologies announced a $270M all‑cash acquisition of digital pathology provider Proscia, a primary corporate event.
likely upside as the market prices in the strategic acquisition.
M&A of this size for a mid‑cap company is material and the transaction is newly disclosed.
Market effects
strengthens Agilent's position in the life‑sciences diagnostics sector.
U.S. biotech and diagnostics markets may see increased M&A activity.
Adds to broader trend of consolidation in digital pathology worldwide.
Counterpoint
The acquisition could strain Agilent's balance sheet and dilute earnings if integration costs rise.
Key entities
- CompanyAgilent Technologies
U.S. life‑sciences and diagnostics equipment maker.
- CompanyProscia
Digital pathology software provider (private).
